Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment

Clinical Immunology

Volumn 149, Issue 1, 2013, Pages 97-110

  Govindaraj, Chindu ^a   Scalzo Inguanti, Karen ^a   Madondo, Mutsa ^a   Hallo, Julene ^b   Flanagan, Katie ^a,c   Quinn, Michael ^b   Plebanski, Magdalena ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

Ascites; Immune suppression; Ovarian cancer; Regulatory T cells; TNF receptor 2

Indexed keywords

5' NUCLEOTIDASE; CD39 ANTIGEN; GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; ASCITES; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; SURVIVAL RATE; TH1 CELL; TUMOR MICROENVIRONMENT;

ASCITES;; IMMUNE SUPPRESSION; OVARIAN CANCER;; REGULATORY T CELLS;; TNF RECEPTOR 2;;

5'-NUCLEOTIDASE; AGED; ANTIGENS, CD; APYRASE; ASCITES; CTLA-4 ANTIGEN; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GPI-LINKED PROTEINS; HUMANS; LEUKOCYTES, MONONUCLEAR; MEMBRANE PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84882609015     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.07.003     Document Type: Article

References (61)

1. Marchetti C., Pisano C., Facchini G., Bruni G.S., Magazzino F.P., Losito S., Pignata S. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert. Rev. Anticancer. Ther. 2010, 10:47-60.
2. Gardner G.J., Jewell E.L. Current and future directions of clinical trials for ovarian cancer. Cancer Control 2011, 18:44-51.
3. Gavalas N.G., Tsiatas M., Tsitsilonis O., Politi E., Ioannou K., Ziogas A.C., Rodolakis A., Vlahos G., Thomakos N., Haidopoulos D., Terpos E., Antsaklis A., Dimopoulos M.A., Bamias A. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br. J. Cancer 2012, 107:1869-1875.
4. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
5. Wolf D., Wolf A.M., Rumpold H., Fiegl H., Zeimet A.G., Muller-Holzner E., Deibl M., Gastl G., Gunsilius E., Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 2005, 11:8326-8331.
6. Ge Y., Domschke C., Stoiber N., Schott S., Heil J., Rom J., Blumenstein M., Thum J., Sohn C., Schneeweiss A., Beckhove P., Schuetz F. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol. Immunother. 2012, 61:353-362.
7. Curiel T.J., Barnett B., Kryczek I., Cheng P., Zou W. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Cancer Immun. 2006, 6(Suppl. 1):20.
8. Friedline R.H., Brown D.S., Nguyen H., Kornfeld H., Lee J., Zhang Y., Appleby M., Der S.D., Kang J., Chambers C.A. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J. Exp. Med. 2009, 206:421-434.
9. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., Chen J.F., Enjyoji K., Linden J., Oukka M., Kuchroo V.K., Strom T.B., Robson S.C. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204:1257-1265.
10. Wang R., Wan Q., Kozhaya L., Fujii H., Unutmaz D. Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PLoS One 2008, 3:e2705.
11. Stagg J., Divisekera U., Duret H., Sparwasser T., Teng M.W., Darcy P.K., Smyth M.J. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011, 71:2892-2900.
12. Mandapathil M., Szczepanski M.J., Szajnik M., Ren J., Lenzner D.E., Jackson E.K., Gorelik E., Lang S., Johnson J.T., Whiteside T.L. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin. Cancer Res. 2009, 15:6348-6357.
13. Feng L., Sun X., Csizmadia E., Han L., Bian S., Murakami T., Wang X., Robson S.C., Wu Y. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 2011, 13:206-216.
14. Goding J.W. Ecto-enzymes: physiology meets pathology. J. Leukoc. Biol. 2000, 67:285-311.
15. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010, 10:490-500.
16. Huehn J., Siegmund K., Lehmann J.C., Siewert C., Haubold U., Feuerer M., Debes G.F., Lauber J., Frey O., Przybylski G.K., Niesner U., de la Rosa M., Schmidt C.A., Brauer R., Buer J., Scheffold A., Hamann A. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J. Exp. Med. 2004, 199:303-313.
17. Scholzen A., Mittag D., Rogerson S.J., Cooke B.M., Plebanski M. Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta. PLoS Pathog. 2009, 5:e1000543.
18. Chen X., Subleski J.J., Hamano R., Howard O.M., Wiltrout R.H., Oppenheim J.J. Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur. J. Immunol. 2010, 40:1099-1106.
19. Mercer F., Kozhaya L., Unutmaz D. Expression and function of TNF and IL-1 receptors on human regulatory T cells. PLoS One 2010, 5:e8639.
20. Maccio A., Madeddu C. Inflammation and ovarian cancer. Cytokine 2012, 58:133-147.
21. Moradi M.M., Carson L.F., Weinberg B., Haney A.F., Twiggs L.B., Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993, 72:2433-2440.
22. Kulbe H., Chakravarty P., Leinster D.A., Charles K.A., Kwong J., Thompson R.G., Coward J.I., Schioppa T., Robinson S.C., Gallagher W.M., Galletta L., Salako M.A., Smyth J.F., Hagemann T., Brennan D.J., Bowtell D.D., Balkwill F.R. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012, 72:66-75.
23. Szlosarek P.W., Grimshaw M.J., Kulbe H., Wilson J.L., Wilbanks G.D., Burke F., Balkwill F.R. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol. Cancer Ther. 2006, 5:382-390.
24. Lee H.Y., Hong Y.K., Yun H.J., Kim Y.M., Kim J.R., Yoo W.H. Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus. Rheumatology (Oxford) 2008, 47:789-794.
25. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25 high regulatory cells in human peripheral blood. J. Immunol. 2001, 167:1245-1253.
26. Minigo G., Woodberry T., Piera K.A., Salwati E., Tjitra E., Kenangalem E., Price R.N., Engwerda C.R., Anstey N.M., Plebanski M. Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog. 2009, 5:e1000402.
27. Chen X., Subleski J.J., Kopf H., Howard O.M., Mannel D.N., Oppenheim J.J. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J. Immunol. 2008, 180:6467-6471.
28. Munson M.E. An improved technique for calculating relative response in cellular proliferation experiments. Cytometry A 2010, 77:909-910.
29. Brusko T.M., Hulme M.A., Myhr C.B., Haller M.J., Atkinson M.A. Assessing the in vitro suppressive capacity of regulatory T cells. Immunol. Invest 2007, 36:607-628.
30. Shevach E.M. Fatal attraction: tumors beckon regulatory T cells. Nat. Med. 2004, 10:900-901.
31. Beyer M., Schultze J.L. Regulatory T cells in cancer. Blood 2006, 108:804-811.
32. Mougiakakos D., Choudhury A., Lladser A., Kiessling R., Johansson C.C. Regulatory T cells in cancer. Adv. Cancer Res. 2010, 107:57-117.
33. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
34. Stagg J., Smyth M.J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010, 29:5346-5358.
35. Mandapathil M., Hilldorfer B., Szczepanski M.J., Czystowska M., Szajnik M., Ren J., Lang S., Jackson E.K., Gorelik E., Whiteside T.L. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem. 2010, 285:7176-7186.
36. Fredholm B.B., Chern Y., Franco R., Sitkovsky M. Aspects of the general biology of adenosine A2A signaling. Prog. Neurobiol. 2007, 83:263-276.
37. Mandapathil M., Szczepanski M.J., Szajnik M., Ren J., Jackson E.K., Johnson J.T., Gorelik E., Lang S., Whiteside T.L. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J. Biol. Chem. 2010, 285:27571-27580.
38. Bynoe M.S., Viret C. Foxp3+CD4+ T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol. 2008, 29:99-102.
39. Wang R., Kozhaya L., Mercer F., Khaitan A., Fujii H., Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13439-13444.
40. Probst-Kepper M., Buer J. FOXP3 and GARP (LRRC32): the master and its minion. Biol. Direct 2010, 5:8.
41. Battaglia M., Roncarolo M.G. The Tregs' world according to GARP. Eur. J. Immunol. 2009, 39:3296-3300.
42. Stockis J., Colau D., Coulie P.G., Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur. J. Immunol. 2009, 39:3315-3322.
43. Tran D.Q., Andersson J., Wang R., Ramsey H., Unutmaz D., Shevach E.M. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13445-13450.
44. Glinka Y., Prud'homme G.J. Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J. Leukoc. Biol. 2008, 84:302-310.
45. Glinka Y., Stoilova S., Mohammed N., Prud'homme G.J. Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis 2011, 32:613-621.
46. Jung Y.W., Seong S.J., Park C.T. Proliferation of CD4CD25Foxp3 regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma. J. Gynecol. Oncol. 2010, 21:132.
47. Hamano R., Huang J., Yoshimura T., Oppenheim J.J., Chen X. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur. J. Immunol. 2011, 41:2010-2020.
48. Hurteau J.A., Simon H.U., Kurman C., Rubin L., Mills G.B. Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. Am. J. Obstet. Gynecol. 1994, 170:918-928.
49. van Mierlo G.J., Scherer H.U., Hameetman M., Morgan M.E., Flierman R., Huizinga T.W., Toes R.E. Cutting edge: TNFR-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J. Immunol. 2008, 180:2747-2751.
50. Pedersen A.E., Lauritsen J.P. CD25 shedding by human natural occurring CD4+CD25+ regulatory T cells does not inhibit the action of IL-2. Scand. J. Immunol. 2009, 70:40-43.
51. Onsrud M., Shabana A., Austgulen R., Nustad K. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer. Gynecol. Oncol. 1995, 57:183-187.
52. Chen X., Hamano R., Subleski J.J., Hurwitz A.A., Howard O.M., Oppenheim J.J. Expression of costimulatory TNFR2 induces resistance of CD4(+)FoxP3(-) conventional T cells to suppression by CD4(+)FoxP3(+) regulatory T Cells. J. Immunol. 2010, 185:174-182.
53. Baecher-Allan C., Viglietta V., Hafler D.A. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J. Immunol. 2002, 169:6210-6217.
54. Thorborn G., Pomeroy L., Isohanni H., Perry M., Peters B., Vyakarnam A. Increased sensitivity of CD4+ T-effector cells to CD4+CD25+ Treg suppression compensates for reduced Treg number in asymptomatic HIV-1 infection. PLoS One 2010, 5:e9254.
55. Lin Y.C., Chang L.Y., Huang C.T., Peng H.M., Dutta A., Chen T.C., Yeh C.T., Lin C.Y. Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. J. Immunol. 2009, 182:6095-6104.
56. Rech A.J., Mick R., Martin S., Recio A., Aqui N.A., Powell D.J., Colligon T.A., Trosko J.A., Leinbach L.I., Pletcher C.H., Tweed C.K., DeMichele A., Fox K.R., Domchek S.M., Riley J.L., Vonderheide R.H. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 2012, 4:134ra62.
57. Stagg J., Divisekera U., McLaughlin N., Sharkey J., Pommey S., Denoyer D., Dwyer K.M., Smyth M.J. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1547-1552.
58. Takaku S., Terabe M., Ambrosino E., Peng J., Lonning S., McPherson J.M., Berzofsky J.A. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int. J. Cancer 2010, 126:1666-1674.
59. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., Morton K.E., Mavroukakis S.A., Duray P.H., Steinberg S.M., Allison J.P., Davis T.A., Rosenberg S.A. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8372-8377.
60. Kissick H.T., Ireland D.J., Krishnan S., Madondo M., Beilharz M.W. Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy. Immunol. Cell Biol. 2012, 90:822-826.
61. van der Most R.G., Currie A.J., Mahendran S., Prosser A., Darabi A., Robinson B.W., Nowak A.K., Lake R.A. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol. Immunother. 2009, 58:1219-1228.